Pancreatic Cancer

  • Savio George Barreto


The incidence of pancreatic cancer is on the rise [1, 2]. Surgery has traditionally been considered the cornerstone in the management of resectable pancreatic cancer [3, 4]. However, we now know that improved outcomes can be achieved by combining surgery with chemotherapy under the broad umbrella of multimodality therapy [5, 6]. This multimodality approach is best suited to only 20% of patients with pancreatic cancer who present when the disease is still amenable to surgical resection. The vast majority of patients, though, present with advanced disease where the aim of therapy is disease control through efforts directed at retarding its progression [7–9].



Dr. Amit Bhasin (Consultant Medical Gastroenterologist—Medanta Institute of Digestive and Hepatobiliary Sciences) and Dr. Arvind Pandey (Consultant Radiologist—Medanta, The Medicity) for the illustrations in this chapter.


  1. 1.
    Yeo TP, Lowenfels AB. Demographics and epidemiology of pancreatic cancer. Cancer J. 2012;18(6):477–84.PubMedCrossRefGoogle Scholar
  2. 2.
    Dhir V, Mohandas KM. Epidemiology of digestive tract cancers in India IV. Gall bladder and pancreas. Indian J Gastroenterol. 1999;18(1):24–8.PubMedGoogle Scholar
  3. 3.
    Janes RH Jr, Niederhuber JE, Chmiel JS, Winchester DP, Ocwieja KC, Karnell JH, et al. National patterns of care for pancreatic cancer. Results of a survey by the Commission on Cancer. Ann Surg. 1996;223(3):261–72.PubMedPubMedCentralCrossRefGoogle Scholar
  4. 4.
    Sener SF, Fremgen A, Menck HR, Winchester DP. Pancreatic cancer: a report of treatment and survival trends for 100,313 patients diagnosed from 1985-1995, using the National Cancer Database. J Am Coll Surg. 1999;189(1):1–7.PubMedCrossRefGoogle Scholar
  5. 5.
    Labori KJ, Katz MH, Tzeng CW, Bjornbeth BA, Cvancarova M, Edwin B, et al. Impact of early disease progression and surgical complications on adjuvant chemotherapy completion rates and survival in patients undergoing the surgery first approach for resectable pancreatic ductal adenocarcinoma – a population-based cohort study. Acta Oncol. 2016;55(3):265–77.PubMedCrossRefGoogle Scholar
  6. 6.
    Valle JW, Palmer D, Jackson R, Cox T, Neoptolemos JP, Ghaneh P, et al. Optimal duration and timing of adjuvant chemotherapy after definitive surgery for ductal adenocarcinoma of the pancreas: ongoing lessons from the ESPAC-3 study. J Clin Oncol. 2014;32(6):504–12.PubMedCrossRefGoogle Scholar
  7. 7.
    Huguet F, Girard N, Guerche CS, Hennequin C, Mornex F, Azria D. Chemoradiotherapy in the management of locally advanced pancreatic carcinoma: a qualitative systematic review. J Clin Oncol. 2009;27(13):2269–77.PubMedCrossRefGoogle Scholar
  8. 8.
    Conroy T, Desseigne F, Ychou M, Bouche O, Guimbaud R, Becouarn Y, et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med. 2011;364(19):1817–25.PubMedCrossRefGoogle Scholar
  9. 9.
    Von Hoff DD, Ervin T, Arena FP, Chiorean EG, Infante J, Moore M, et al. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med. 2013;369(18):1691–703.CrossRefGoogle Scholar
  10. 10.
    Nienhuijs SW, van den Akker SA, de Vries E, de Hingh IH, Visser O, Lemmens VE. Nationwide improvement of only short-term survival after resection for pancreatic cancer in the Netherlands. Pancreas. 2012;41(7):1063–6.PubMedCrossRefGoogle Scholar
  11. 11.
    Bosetti C, Bertuccio P, Malvezzi M, Levi F, Chatenoud L, Negri E, et al. Cancer mortality in Europe, 2005-2009, and an overview of trends since 1980. Ann Oncol. 2013;24(10):2657–71.PubMedCrossRefGoogle Scholar
  12. 12.
    A snapshot of pancreatic cancer – National Cancer Institute 2016.
  13. 13.
    Lucas AL, Malvezzi M, Carioli G, Negri E, La Vecchia C, Boffetta P, et al. Global trends in pancreatic cancer mortality from 1980 through 2013 and predictions for 2017. Clin Gastroenterol Hepatol. 2016;14(10):1452–1462.e4.PubMedPubMedCentralCrossRefGoogle Scholar
  14. 14.
    Siegel RL, Miller KD, Jemal A. Cancer statistics, 2016. CA Cancer J Clin. 2016;66(1):7–30.PubMedCrossRefGoogle Scholar
  15. 15.
    Barreto SG, Windsor JA. Justifying vein resection with pancreatoduodenectomy. Lancet Oncol. 2016;17(3):e118–24.PubMedCrossRefGoogle Scholar
  16. 16.
    Worldwide cancer statistics 2016 [July 5, 2016].
  17. 17.
    Ferlay J, Steliarova-Foucher E, Lortet-Tieulent J, Rosso S, Coebergh JW, Comber H, et al. Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012. Eur J Cancer. 2013;49(6):1374–403.PubMedCrossRefGoogle Scholar
  18. 18.
    Shrikhande SV, Barreto SG, Somashekar BA, Suradkar K, Shetty GS, Talole S, et al. Evolution of pancreatoduodenectomy in a tertiary cancer center in India: improved results from service reconfiguration. Pancreatology. 2013;13(1):63–71.PubMedCrossRefGoogle Scholar
  19. 19.
    Chang KJ, Parasher G, Christie C, Largent J, Anton-Culver H. Risk of pancreatic adenocarcinoma: disparity between African Americans and other race/ethnic groups. Cancer. 2005;103(2):349–57.PubMedCrossRefGoogle Scholar
  20. 20.
    Wray CJ, Castro-Echeverry E, Silberfein EJ, Ko TC, Kao LS. A multi-institutional study of pancreatic cancer in Harris County, Texas: race predicts treatment and survival. Ann Surg Oncol. 2012;19(9):2776–81.PubMedCrossRefGoogle Scholar
  21. 21.
    Pulte D, Redaniel MT, Brenner H, Jeffreys M. Changes in survival by ethnicity of patients with cancer between 1992–1996 and 2002–2006: is the discrepancy decreasing? Ann Oncol. 2012;23(9):2428–34.PubMedCrossRefGoogle Scholar
  22. 22.
    Zeng C, Wen W, Morgans AK, Pao W, Shu XO, Zheng W. Disparities by race, age, and sex in the improvement of survival for major cancers: results from the National Cancer Institute Surveillance, Epidemiology, and End Results (SEER) Program in the United States, 1990 to 2010. JAMA Oncol. 2015;1(1):88–96.PubMedPubMedCentralCrossRefGoogle Scholar
  23. 23.
    Eldridge RC, Gapstur SM, Newton CC, Goodman M, Patel AV, Jacobs EJ. Jewish ethnicity and pancreatic cancer mortality in a large U.S. cohort. Cancer Epidemiol Biomark Prev. 2011;20(4):691–8.CrossRefGoogle Scholar
  24. 24.
    Yadav D, Lowenfels AB. The epidemiology of pancreatitis and pancreatic cancer. Gastroenterology. 2013;144(6):1252–61.PubMedPubMedCentralCrossRefGoogle Scholar
  25. 25.
    Phillips AR, Lawes CM, Cooper GJ, Windsor JA. Ethnic disparity of pancreatic cancer in New Zealand. Int J Gastrointest Cancer. 2002;31(1–3):137–45.PubMedCrossRefGoogle Scholar
  26. 26.
    Yadav S, Sharma P, Zakalik D. Comparison of demographics, tumor characteristics, and survival between pancreatic adenocarcinomas and pancreatic neuroendocrine tumors: a population-based study. Am J Clin Oncol 2016.Google Scholar
  27. 27.
    Eguchi H, Yamaue H, Unno M, Mizuma M, Hamada S, Igarashi H, et al. Clinicopathological characteristics of young patients with pancreatic cancer: an analysis of data from pancreatic cancer registry of Japan pancreas society. Pancreas. 2016;45(10):1411–7.PubMedCrossRefGoogle Scholar
  28. 28.
    Piciucchi M, Capurso G, Valente R, Larghi A, Archibugi L, Signoretti M, et al. Early onset pancreatic cancer: risk factors, presentation and outcome. Pancreatology. 2015;15(2):151–5.PubMedCrossRefGoogle Scholar
  29. 29.
    Syngal S, Brand RE, Church JM, Giardiello FM, Hampel HL, Burt RW. ACG clinical guideline: genetic testing and management of hereditary gastrointestinal cancer syndromes. Am J Gastroenterol. 2015;110(2):223–62.PubMedPubMedCentralCrossRefGoogle Scholar
  30. 30.
    Fiederling J, Shams AZ, Haug U. Validity of self-reported family history of cancer: a systematic literature review on selected cancers. Int J Cancer. 2016;139(7):1449–60.PubMedCrossRefGoogle Scholar
  31. 31.
    Petersen GM, de Andrade M, Goggins M, Hruban RH, Bondy M, Korczak JF, et al. Pancreatic cancer genetic epidemiology consortium. Cancer Epidemiol Biomark Prev. 2006;15(4):704–10.CrossRefGoogle Scholar
  32. 32.
    Grant RC, Selander I, Connor AA, Selvarajah S, Borgida A, Briollais L, et al. Prevalence of germline mutations in cancer predisposition genes in patients with pancreatic cancer. Gastroenterology. 2015;148(3):556–64.PubMedCrossRefGoogle Scholar
  33. 33.
    Schneider R, Slater EP, Sina M, Habbe N, Fendrich V, Matthai E, et al. German national case collection for familial pancreatic cancer (FaPaCa): ten years experience. Fam Cancer. 2011;10(2):323–30.PubMedCrossRefGoogle Scholar
  34. 34.
    Howes N, Lerch MM, Greenhalf W, Stocken DD, Ellis I, Simon P, et al. Clinical and genetic characteristics of hereditary pancreatitis in Europe. Clin Gastroenterol Hepatol. 2004;2(3):252–61.PubMedCrossRefPubMedCentralGoogle Scholar
  35. 35.
    Lowenfels AB, Maisonneuve P, DiMagno EP, Elitsur Y, Gates LK Jr, Perrault J, et al. Hereditary pancreatitis and the risk of pancreatic cancer. International Hereditary Pancreatitis Study Group. J Natl Cancer Inst. 1997;89(6):442–6.PubMedCrossRefGoogle Scholar
  36. 36.
    Underhill ML, Germansky KA, Yurgelun MB. Advances in hereditary colorectal and pancreatic cancers. Clin Ther. 2016;38(7):1600–21.PubMedPubMedCentralCrossRefGoogle Scholar
  37. 37.
    Slater EP, Langer P, Niemczyk E, Strauch K, Butler J, Habbe N, et al. PALB2 mutations in European familial pancreatic cancer families. Clin Genet. 2010;78(5):490–4.PubMedCrossRefGoogle Scholar
  38. 38.
    Zhen DB, Rabe KG, Gallinger S, Syngal S, Schwartz AG, Goggins MG, et al. BRCA1, BRCA2, PALB2, and CDKN2A mutations in familial pancreatic cancer: a PACGENE study. Genet Med. 2015;17(7):569–77.PubMedCrossRefGoogle Scholar
  39. 39.
    Kastrinos F, Mukherjee B, Tayob N, Wang F, Sparr J, Raymond VM, et al. Risk of pancreatic cancer in families with Lynch syndrome. JAMA. 2009;302(16):1790–5.PubMedPubMedCentralCrossRefGoogle Scholar
  40. 40.
    Goldgar DE. Analysis of familial breast cancer in genetic analysis workshop 9: summary of findings. Genet Epidemiol. 1995;12(6):833–6.PubMedCrossRefGoogle Scholar
  41. 41.
    Thompson D, Szabo CI, Mangion J, Oldenburg RA, Odefrey F, Seal S, et al. Evaluation of linkage of breast cancer to the putative BRCA3 locus on chromosome 13q21 in 128 multiple case families from the Breast Cancer Linkage Consortium. Proc Natl Acad Sci U S A. 2002;99(2):827–31.PubMedPubMedCentralCrossRefGoogle Scholar
  42. 42.
    Hofstatter EW, Domchek SM, Miron A, Garber J, Wang M, Componeschi K, et al. PALB2 mutations in familial breast and pancreatic cancer. Fam Cancer. 2011;10(2):225–31.PubMedCrossRefGoogle Scholar
  43. 43.
    Roberts NJ, Jiao Y, Yu J, Kopelovich L, Petersen GM, Bondy ML, et al. ATM mutations in patients with hereditary pancreatic cancer. Cancer Discov. 2012;2(1):41–6.PubMedCrossRefGoogle Scholar
  44. 44.
    Humphris JL, Biankin AV. Diagnosis and management of hereditary pancreatic cancer. Recent Results Cancer Res. 2016;205:61–83.PubMedCrossRefGoogle Scholar
  45. 45.
    Segura PP, Ponce CG, Ramon YCT, Blanch RS, Aranda E. Hereditary pancreatic cancer: molecular bases and their application in diagnosis and clinical management: a guideline of the TTD group. Clin Transl Oncol. 2012;14(8):553–63.PubMedCrossRefGoogle Scholar
  46. 46.
    Iodice S, Gandini S, Maisonneuve P, et al. Tobacco and the risk of pancreatic cancer: a review and metaanalysis. Langenbeck’s Arch Surg. 2008;393:535–45.CrossRefGoogle Scholar
  47. 47.
    Duell EJ. Epidemiology and potential mechanisms of tobacco smoking and heavy alcohol consumption in pancreatic cancer. Mol Carcinog. 2012;51:40–52.PubMedCrossRefGoogle Scholar
  48. 48.
    McWilliams RR, Maisonneuve P, Bamlet WR, Petersen GM, Li D, Risch HA, et al. Risk factors for early-onset and very-early-onset pancreatic adenocarcinoma: a pancreatic cancer case-control consortium (PanC4) analysis. Pancreas. 2016;45(2):311–6.PubMedPubMedCentralCrossRefGoogle Scholar
  49. 49.
    Anderson MA, Zolotarevsky E, Cooper KL, Sherman S, Shats O, Whitcomb DC, et al. Alcohol and tobacco lower the age of presentation in sporadic pancreatic cancer in a dose-dependent manner: a multicenter study. Am J Gastroenterol. 2012;107(11):1730–9.PubMedPubMedCentralCrossRefGoogle Scholar
  50. 50.
    Lucenteforte E, La Vecchia C, Silverman D, Petersen GM, Bracci PM, Ji BT, et al. Alcohol consumption and pancreatic cancer: a pooled analysis in the International Pancreatic Cancer Case-Control Consortium (PanC4). Ann Oncol. 2012;23(2):374–82.PubMedCrossRefGoogle Scholar
  51. 51.
    Ben Q, Xu M, Ning X, Liu J, Hong S, Huang W, et al. Diabetes mellitus and risk of pancreatic cancer: a meta-analysis of cohort studies. Eur J Cancer. 2011;47(13):1928–37.PubMedCrossRefGoogle Scholar
  52. 52.
    Kasuga M, Ueki K, Tajima N, Noda M, Ohashi K, Noto H, et al. Report of the Japan diabetes society/Japanese cancer association joint committee on diabetes and cancer. Cancer Sci. 2013;104(7):965–76.PubMedCrossRefGoogle Scholar
  53. 53.
    Shen H, Zhan M, Wang W, Yang D, Wang J. Impact of diabetes mellitus on the survival of pancreatic cancer: a meta-analysis. Onco Targets Ther. 2016;9:1679–88.PubMedPubMedCentralGoogle Scholar
  54. 54.
    Johnson JA, Bowker SL, Richardson K, Marra CA. Time-varying incidence of cancer after the onset of type 2 diabetes: evidence of potential detection bias. Diabetologia. 2011;54(9):2263–71.PubMedCrossRefGoogle Scholar
  55. 55.
    Li D, Tang H, Hassan MM, Holly EA, Bracci PM, Silverman DT. Diabetes and risk of pancreatic cancer: a pooled analysis of three large case-control studies. Cancer Causes Control. 2011;22(2):189–97.PubMedCrossRefGoogle Scholar
  56. 56.
    Jiao L, Berrington de Gonzalez A, Hartge P, Pfeiffer RM, Park Y, Freedman DM, et al. Body mass index, effect modifiers, and risk of pancreatic cancer: a pooled study of seven prospective cohorts. Cancer Causes Control. 2010;21(8):1305–14.PubMedPubMedCentralCrossRefGoogle Scholar
  57. 57.
    Arslan AA, Helzlsouer KJ, Kooperberg C, Shu XO, Steplowski E, Bueno-de-Mesquita HB, et al. Anthropometric measures, body mass index, and pancreatic cancer: a pooled analysis from the Pancreatic Cancer Cohort Consortium (PanScan). Arch Intern Med. 2010;170(9):791–802.PubMedPubMedCentralCrossRefGoogle Scholar
  58. 58.
    Zavoral M, Minarikova P, Zavada F, Salek C, Minarik M. Molecular biology of pancreatic cancer. World J Gastroenterol. 2011;17(24):2897–908.PubMedPubMedCentralCrossRefGoogle Scholar
  59. 59.
    Hirota M, Shimosegawa T, Masamune A, Kikuta K, Kume K, Hamada S, et al. The seventh nationwide epidemiological survey for chronic pancreatitis in Japan: clinical significance of smoking habit in Japanese patients. Pancreatology. 2014;14(6):490–6.PubMedCrossRefGoogle Scholar
  60. 60.
    Lowenfels AB, Maisonneuve P, Cavallini G, Ammann RW, Lankisch PG, Andersen JR, et al. Pancreatitis and the risk of pancreatic cancer. International Pancreatitis Study Group. N Engl J Med. 1993;328(20):1433–7.PubMedCrossRefPubMedCentralGoogle Scholar
  61. 61.
    Chari S, Mohan V, Pitchumoni C, et al. Risk of pancreatic carcinoma in tropical calcific pancreatitis. Pancreas. 1993;9:62–6.CrossRefGoogle Scholar
  62. 62.
    Lowenfels AB, Maisonneuve P, Whitcomb DC, Lerch MM, DiMagno EP. Cigarette smoking as a risk factor for pancreatic cancer in patients with hereditary pancreatitis. JAMA. 2001;286(2):169–70.PubMedCrossRefGoogle Scholar
  63. 63.
    Shrikhande S, Barreto G, Koliopanos A. Pancreatic carcinogenesis: the impact of chronic pancreatitis and its clinical relevance. Indian J Cancer. 2009;46:288–96.PubMedCrossRefGoogle Scholar
  64. 64.
    Ananthakrishnan AN, Cagan A, Gainer VS, Cheng SC, Cai T, Szolovits P, et al. Mortality and extraintestinal cancers in patients with primary sclerosing cholangitis and inflammatory bowel disease. J Crohns Colitis. 2014;8(9):956–63.PubMedPubMedCentralCrossRefGoogle Scholar
  65. 65.
    Boonstra K, Weersma RK, van Erpecum KJ, Rauws EA, Spanier BW, Poen AC, et al. Population-based epidemiology, malignancy risk, and outcome of primary sclerosing cholangitis. Hepatology. 2013;58(6):2045–55.PubMedCrossRefGoogle Scholar
  66. 66.
    Michaud DS. Role of bacterial infections in pancreatic cancer. Carcinogenesis. 2013;34(10):2193–7.PubMedPubMedCentralCrossRefGoogle Scholar
  67. 67.
    Tanaka M, Fernandez-Del Castillo C, Adsay V, Chari S, Falconi M, Jang JY, et al. International consensus guidelines 2012 for the management of IPMN and MCN of the pancreas. Pancreatology. 2012;12(3):183–97.PubMedCrossRefPubMedCentralGoogle Scholar
  68. 68.
    Hruban RH, Maitra A, Goggins M. Update on pancreatic intraepithelial neoplasia. Int J Clin Exp Pathol. 2008;1(4):306–16.PubMedPubMedCentralGoogle Scholar
  69. 69.
    Barreto SG, Neale RE. Vitamin D and pancreatic cancer. Cancer Lett. 2015;368(1):1–6.PubMedCrossRefGoogle Scholar
  70. 70.
    Hruban RH, Fukushima N. Pancreatic adenocarcinoma: update on the surgical pathology of carcinomas of ductal origin and PanINs. Mod Pathol. 2007;20(Suppl 1):S61–70.PubMedCrossRefGoogle Scholar
  71. 71.
    Hruban R, Klimstra D, Pitman M, editors. Tumors of the pancreas. Atlas of Tumor Pathology. Washington, DC;2006.Google Scholar
  72. 72.
    Lin F, Chen ZE, Wang HL. Utility of immunohistochemistry in the pancreatobiliary tract. Arch Pathol Lab Med. 2015;139(1):24–38.PubMedCrossRefGoogle Scholar
  73. 73.
    Bailey P, Chang DK, Nones K, Johns AL, Patch AM, Gingras MC, et al. Genomic analyses identify molecular subtypes of pancreatic cancer. Nature. 2016;531(7592):47–52.PubMedCrossRefGoogle Scholar
  74. 74.
    Kimura W, Futakawa N, Yamagata S, Wada Y, Kuroda A, Muto T, et al. Different clinicopathologic findings in two histologic types of carcinoma of papilla of Vater. Jpn J Cancer Res. 1994;85(2):161–6.PubMedPubMedCentralCrossRefGoogle Scholar
  75. 75.
    Kim WS, Choi DW, Choi SH, Heo JS, You DD, Lee HG. Clinical significance of pathologic subtype in curatively resected ampulla of vater cancer. J Surg Oncol. 2012;105(3):266–72.PubMedCrossRefGoogle Scholar
  76. 76.
    Kimura W, Futakawa N, Zhao B. Neoplastic diseases of the papilla of Vater. J Hepato-Biliary-Pancreat Surg. 2004;11(4):223–31.CrossRefGoogle Scholar
  77. 77.
    Ang DC, Shia J, Tang LH, Katabi N, Klimstra DS. The utility of immunohistochemistry in subtyping adenocarcinoma of the ampulla of vater. Am J Surg Pathol. 2014;38(10):1371–9.PubMedCrossRefGoogle Scholar
  78. 78.
    Cubilla AL, Fitzgerald PJ. Morphological lesions associated with human primary invasive nonendocrine pancreas cancer. Cancer Res. 1976;36(7 PT 2):2690–8.PubMedGoogle Scholar
  79. 79.
    Kozuka S, Sassa R, Taki T, Masamoto K, Nagasawa S, Saga S, et al. Relation of pancreatic duct hyperplasia to carcinoma. Cancer. 1979;43(4):1418–28.PubMedCrossRefGoogle Scholar
  80. 80.
    Hruban RH, Adsay NV, Albores-Saavedra J, Compton C, Garrett ES, Goodman SN, et al. Pancreatic intraepithelial neoplasia: a new nomenclature and classification system for pancreatic duct lesions. Am J Surg Pathol. 2001;25(5):579–86.PubMedCrossRefGoogle Scholar
  81. 81.
    Hruban R, Pitman M, Klimstra D, editors. Tumors of the pancreas Atlas of tumor pathology, 4th series. Washington, DC: American Registry of Pathology and Armed Forces Institute of Pathology; 2007.Google Scholar
  82. 82.
    Distler M, Aust D, Weitz J, Pilarsky C, Grutzmann R. Precursor lesions for sporadic pancreatic cancer: PanIN, IPMN, and MCN. Biomed Res Int. 2014;2014:474905.PubMedPubMedCentralCrossRefGoogle Scholar
  83. 83.
    Murphy SJ, Hart SN, Lima JF, Kipp BR, Klebig M, Winters JL, et al. Genetic alterations associated with progression from pancreatic intraepithelial neoplasia to invasive pancreatic tumor. Gastroenterology. 2013;145(5):1098–109 e1.PubMedPubMedCentralCrossRefGoogle Scholar
  84. 84.
    Brune K, Abe T, Canto M, O'Malley L, Klein AP, Maitra A, et al. Multifocal neoplastic precursor lesions associated with lobular atrophy of the pancreas in patients having a strong family history of pancreatic cancer. Am J Surg Pathol. 2006;30(9):1067–76.PubMedPubMedCentralGoogle Scholar
  85. 85.
    Detlefsen S, Sipos B, Feyerabend B, Kloppel G. Pancreatic fibrosis associated with age and ductal papillary hyperplasia. Virchows Arch. 2005;447(5):800–5.PubMedCrossRefGoogle Scholar
  86. 86.
    Maitra A, Adsay NV, Argani P, Iacobuzio-Donahue C, De Marzo A, Cameron JL, et al. Multicomponent analysis of the pancreatic adenocarcinoma progression model using a pancreatic intraepithelial neoplasia tissue microarray. Mod Pathol. 2003;16(9):902–12.PubMedCrossRefGoogle Scholar
  87. 87.
    Yachida S, White C, Naito Y, Zhong Y, Brosnan J. Clinical significance of the genetic landscape of pancreatic cancer and implications for identification of potential long-term survivors. Clin Cancer Res. 2012;18(22):6339–47.PubMedPubMedCentralCrossRefGoogle Scholar
  88. 88.
    Hruban RH, Adsay NV. Molecular classification of neoplasms of the pancreas. Hum Pathol. 2009;40(5):612–23.PubMedCrossRefGoogle Scholar
  89. 89.
    Jones S, Zhang X, Parsons DW, Lin JC, Leary RJ, Angenendt P, et al. Core signaling pathways in human pancreatic cancers revealed by global genomic analyses. Science. 2008;321(5897):1801–6.PubMedPubMedCentralCrossRefGoogle Scholar
  90. 90.
    AJCC. In: Edge S, Byrd D, Compton C, et al., editors. Cancer staging manual. 7th ed. New York: Springer; 2009.Google Scholar
  91. 91.
    Howard TJ, Krug JE, Yu J, Zyromski NJ, Schmidt CM, Jacobson LE, et al. A margin-negative R0 resection accomplished with minimal postoperative complications is the surgeon’s contribution to long-term survival in pancreatic cancer. J Gastrointest Surg. 2006;10(10):1338–45. discussion 45-6.PubMedCrossRefGoogle Scholar
  92. 92.
    Esposito I, Kleeff J, Bergmann F, Reiser C, Herpel E, Friess H, et al. Most pancreatic cancer resections are R1 resections. Ann Surg Oncol. 2008;15(6):1651–60.PubMedCrossRefGoogle Scholar
  93. 93.
    Gomez-Mateo Mdel C, Sabater-Orti L, Ferrandez-Izquierdo A. Pathology handling of pancreatoduodenectomy specimens: approaches and controversies. World J Gastrointest Oncol. 2014;6(9):351–9.PubMedCrossRefGoogle Scholar
  94. 94.
    Verbeke CS. Resection margins and R1 rates in pancreatic cancer – are we there yet? Histopathology. 2008;52(7):787–96.PubMedCrossRefGoogle Scholar
  95. 95.
    Verbeke CS, Leitch D, Menon KV, McMahon MJ, Guillou PJ, Anthoney A. Redefining the R1 resection in pancreatic cancer. Br J Surg. 2006;93(10):1232–7.PubMedCrossRefGoogle Scholar
  96. 96.
    Washington K, Berlin J, Branton P, Burgart L, Carter D, Compton C, et al. Protocol for the examination of specimens from patients with carcinoma of the exocrine pancreas: College of American Pathologists; 2013 [updated October 2013 July 7, 2016].
  97. 97.
    Campbell F, Foulis A, Verbeke C. Dataset for histopathological reporting of carcinomas of the pancreas, ampulla of Vater and common bile duct London: The Royal College of Pathologists; 2010 [July 7, 2016].
  98. 98.
    Khalifa MA, Maksymov V, Rowsell C. Retroperitoneal margin of the pancreaticoduodenectomy specimen: anatomic mapping for the surgical pathologist. Virchows Arch. 2009;454(2):125–31.PubMedCrossRefGoogle Scholar
  99. 99.
    Kakar S, Pawlik T, Allen P. Exocrine pancreas. Pancreatic adenocarcinoma. In: Amin M, editor. AJCC cancer staging manual. 8th ed. New York: Springer; 2016.Google Scholar
  100. 100.
    Shrikhande S, Barreto S. Surgery for pancreatic carcinoma: state of the art. Indian J Surg. 2012;74:79–86.PubMedCrossRefGoogle Scholar
  101. 101.
    Barreto G, Shukla PJ, Ramadwar M, Arya S, Shrikhande SV. Cystic tumours of the pancreas. HPB (Oxford). 2007;9(4):259–66.CrossRefGoogle Scholar
  102. 102.
    Barreto S, Shukla P, Shrikhande S. Tumors of the pancreatic body and tail. World J Oncol. 2010;1(2):52–65.PubMedPubMedCentralGoogle Scholar
  103. 103.
    Barreto S, Shukla P, Shrikhande S. Periampullary carcinoma. In: Shrikhande S, Friess H, Buchler M, editors. Surgery of pancreatic tumors. New Delhi: BI Publications; 2007. p. 206–15.Google Scholar
  104. 104.
    Feng B, Song Q. Does the common bile duct dilate after cholecystectomy? Sonographic evaluation in 234 patients. AJR Am J Roentgenol. 1995;165(4):859–61.PubMedCrossRefGoogle Scholar
  105. 105.
    Corazziari ES, Cotton PB. Gallbladder and sphincter of Oddi disorders. Am J Gastroenterol. 2010;105(4):764–9.PubMedCrossRefGoogle Scholar
  106. 106.
    Hendifar A, Osipov A, Khanuja J, Nissen N, Naziri J, Yang W, et al. Influence of body mass index and albumin on perioperative morbidity and clinical outcomes in resected pancreatic adenocarcinoma. PLoS One. 2016;11(3):e0152172.PubMedPubMedCentralCrossRefGoogle Scholar
  107. 107.
    Feyko J, Hazard H, Cardinal J, Thomay A, Cho S. Pancreatectomy in patients with impaired renal function: how risky is it? Am Surg. 2016;82(1):16–21.PubMedGoogle Scholar
  108. 108.
    Myatra S, Divatia JV, Jibhkate B, Barreto GS, Shrikhande SV. Preoperative assessment and optimization in periampullary and pancreatic cancer. Indian J Cancer. 2011;48(1):86–93.PubMedCrossRefGoogle Scholar
  109. 109.
    Goonetilleke KS, Siriwardena AK. Systematic review of carbohydrate antigen (CA 19-9) as a biochemical marker in the diagnosis of pancreatic cancer. Eur J Surg Oncol. 2007;33(3):266–70.PubMedCrossRefGoogle Scholar
  110. 110.
    Bergquist JR, Puig CA, Shubert CR, Groeschl RT, Habermann EB, Kendrick ML, et al. Carbohydrate antigen 19-9 elevation in anatomically resectable, early stage pancreatic cancer is independently associated with decreased overall survival and an indication for neoadjuvant therapy: a National Cancer Database Study. J Am Coll Surg. 2016;223(1):52–65.PubMedCrossRefGoogle Scholar
  111. 111.
    Kim HJ, Lee WJ, Kang CM, Hwang HK, Bang SM, Song SY, et al. Risk factors associated with loco-regional failure after surgical resection in patients with resectable pancreatic cancer. PLoS One. 2016;11(6):e0157196.PubMedPubMedCentralCrossRefGoogle Scholar
  112. 112.
    Williams JL, Kadera BE, Nguyen AH, Muthusamy VR, Wainberg ZA, Hines OJ, et al. CA19-9 normalization during pre-operative treatment predicts longer survival for patients with locally progressed pancreatic cancer. J Gastrointest Surg. 2016;20(7):1331–42.PubMedPubMedCentralCrossRefGoogle Scholar
  113. 113.
    Boone BA, Steve J, Zenati MS, Hogg ME, Singhi AD, Bartlett DL, et al. Serum CA 19-9 response to neoadjuvant therapy is associated with outcome in pancreatic adenocarcinoma. Ann Surg Oncol. 2014;21(13):4351–8.PubMedCrossRefGoogle Scholar
  114. 114.
    Montgomery RC, Hoffman JP, Riley LB, Rogatko A, Ridge JA, Eisenberg BL. Prediction of recurrence and survival by post-resection CA 19-9 values in patients with adenocarcinoma of the pancreas. Ann Surg Oncol. 1997;4(7):551–6.PubMedCrossRefGoogle Scholar
  115. 115.
    Poruk KE, Gay DZ, Brown K, Mulvihill JD, Boucher KM, Scaife CL, et al. The clinical utility of CA 19-9 in pancreatic adenocarcinoma: diagnostic and prognostic updates. Curr Mol Med. 2013;13(3):340–51.PubMedPubMedCentralGoogle Scholar
  116. 116.
    Mery CM, Duarte-Rojo A, Paz-Pineda F, Gomez E, Robles-Diaz G. Does cholestasis change the clinical usefulness of CA 19-9 in pacreatobiliary cancer? Rev Investig Clin. 2001;53(6):511–7.Google Scholar
  117. 117.
    Berger AC, Garcia M Jr, Hoffman JP, Regine WF, Abrams RA, Safran H, et al. Postresection CA 19-9 predicts overall survival in patients with pancreatic cancer treated with adjuvant chemoradiation: a prospective validation by RTOG 9704. J Clin Oncol. 2008;26(36):5918–22.PubMedPubMedCentralCrossRefGoogle Scholar
  118. 118.
    Zhang Y, Yang J, Li H, Wu Y, Zhang H, Chen W. Tumor markers CA19-9, CA242 and CEA in the diagnosis of pancreatic cancer: a meta-analysis. Int J Clin Exp Med. 2015;8(7):11683–91.PubMedPubMedCentralGoogle Scholar
  119. 119.
    Shukla PJ, Barreto SG, Kulkarni A, Nagarajan G, Fingerhut A. Vascular anomalies encountered during pancreatoduodenectomy: do they influence outcomes? Ann Surg Oncol. 2010;17(1):186–93.PubMedCrossRefGoogle Scholar
  120. 120.
    Winston C, Teitcher J. Computed tomography of the liver, biliary tract, and pancreas. In: Blumgart L, Jarnagin W, Belghiti J, Buchler M, Chapman W, D’Angelica M, et al., editors. Blumgart’s surgery of the liver, biliary tract, and pancreas. 1. 5th ed. Philadelphia: Elsevier; 2012. p. 272–312.CrossRefGoogle Scholar
  121. 121.
    Fletcher JG, Wiersema MJ, Farrell MA, Fidler JL, Burgart LJ, Koyama T, et al. Pancreatic malignancy: value of arterial, pancreatic, and hepatic phase imaging with multi-detector row CT. Radiology. 2003;229(1):81–90.PubMedCrossRefGoogle Scholar
  122. 122.
    Shrikhande S, Barreto S, Goel M, Arya S. Multimodality imaging of pancreatic ductal adenocarcinoma: a review of the literature. HPB (Oxford). 2012;14(10):658–68.CrossRefGoogle Scholar
  123. 123.
    Kim JH, Park SH, ES Y, Kim MH, Kim J, Byun JH, et al. Visually isoattenuating pancreatic adenocarcinoma at dynamic-enhanced CT: frequency, clinical and pathologic characteristics, and diagnosis at imaging examinations. Radiology. 2010;257(1):87–96.PubMedCrossRefGoogle Scholar
  124. 124.
    Zhang Y, Huang J, Chen M, Jiao LR. Preoperative vascular evaluation with computed tomography and magnetic resonance imaging for pancreatic cancer: a meta-analysis. Pancreatology. 2012;12(3):227–33.PubMedCrossRefGoogle Scholar
  125. 125.
    Macari M, Spieler B, Kim D, Graser A, Megibow AJ, Babb J, et al. Dual-source dual-energy MDCT of pancreatic adenocarcinoma: initial observations with data generated at 80 kVp and at simulated weighted-average 120 kVp. AJR Am J Roentgenol. 2010;194(1):W27–32.PubMedCrossRefGoogle Scholar
  126. 126.
    Pittayanon R, Imraporn B, Rerknimitr R, Kullavanijaya P. Advances in diagnostic endoscopy for duodenal, including ampullary, adenoma. Dig Endosc. 2014;26(Suppl 2):10–5.PubMedCrossRefGoogle Scholar
  127. 127.
    Shahid MW, Buchner A, Gomez V, Krishna M, Woodward TA, Raimondo M, et al. Diagnostic accuracy of probe-based confocal laser endomicroscopy and narrow band imaging in detection of dysplasia in duodenal polyps. J Clin Gastroenterol. 2012;46(5):382–9.PubMedCrossRefGoogle Scholar
  128. 128.
    Jagannath P, Dhir V, Shrikhande S, Shah RC, Mullerpatan P, Mohandas KM. Effect of preoperative biliary stenting on immediate outcome after pancreaticoduodenectomy. Br J Surg. 2005;92(3):356–61.PubMedCrossRefGoogle Scholar
  129. 129.
    Sewnath ME, Birjmohun RS, Rauws EA, Huibregtse K, Obertop H, Gouma DJ. The effect of preoperative biliary drainage on postoperative complications after pancreaticoduodenectomy. J Am Coll Surg. 2001;192(6):726–34.PubMedCrossRefGoogle Scholar
  130. 130.
    Coates JM, Beal SH, Russo JE, Vanderveen KA, Chen SL, Bold RJ, et al. Negligible effect of selective preoperative biliary drainage on perioperative resuscitation, morbidity, and mortality in patients undergoing pancreaticoduodenectomy. Arch Surg. 2009;144(9):841–7.PubMedCrossRefGoogle Scholar
  131. 131.
    Barreto S, Singh A, Perwaiz A, Singh T, Singh M, Sharma S, et al. Perioperative antimicrobial therapy in preventing infectious complications following pancreatoduodenectomy. Indian J Med Res. 2017;146(4):514–19.Google Scholar
  132. 132.
    Barreto SG, Singh MK, Sharma S, Chaudhary A. Determinants of surgical site infections following pancreatoduodenectomy. World J Surg. 2015;39(10):2557–63.PubMedCrossRefGoogle Scholar
  133. 133.
    Barreto SG, Singh A, Perwaiz A, Singh T, Adlakha R, Singh MK, et al. The cost of pancreatoduodenectomy – an analysis of clinical determinants. Pancreatology. 2016;16(4):652–7.PubMedCrossRefGoogle Scholar
  134. 134.
    Mullen JT, Lee JH, Gomez HF, Ross WA, Fukami N, Wolff RA, et al. Pancreaticoduodenectomy after placement of endobiliary metal stents. J Gastrointest Surg. 2005;9(8):1094–104. discussion 104-5.PubMedCrossRefGoogle Scholar
  135. 135.
    Wasan SM, Ross WA, Staerkel GA, Lee JH. Use of expandable metallic biliary stents in resectable pancreatic cancer. Am J Gastroenterol. 2005;100(9):2056–61.PubMedCrossRefGoogle Scholar
  136. 136.
    Kozarek R. Role of preoperative palliation of jaundice in pancreatic cancer. J Hepatobiliary Pancreat Sci. 2013;20(6):567–72.PubMedCrossRefGoogle Scholar
  137. 137.
    Walter D, van Boeckel PG, Groenen MJ, Weusten BL, Witteman BJ, Tan G, et al. Cost efficacy of metal stents for palliation of extrahepatic bile duct obstruction in a randomized controlled trial. Gastroenterology. 2015;149(1):130–8.PubMedCrossRefGoogle Scholar
  138. 138.
    Dewitt J, Devereaux BM, Lehman GA, Sherman S, Imperiale TF. Comparison of endoscopic ultrasound and computed tomography for the preoperative evaluation of pancreatic cancer: a systematic review. Clin Gastroenterol Hepatol. 2006;4(6):717–25.PubMedCrossRefGoogle Scholar
  139. 139.
    Li JH, He R, Li YM, Cao G, Ma QY, Yang WB. Endoscopic ultrasonography for tumor node staging and vascular invasion in pancreatic cancer: a meta-analysis. Dig Surg. 2014;31(4–5):297–305.PubMedCrossRefGoogle Scholar
  140. 140.
    Yang R, Lu M, Qian X, Chen J, Li L, Wang J, et al. Diagnostic accuracy of EUS and CT of vascular invasion in pancreatic cancer: a systematic review. J Cancer Res Clin Oncol. 2014;140(12):2077–86.PubMedCrossRefGoogle Scholar
  141. 141.
    Farma JM, Santillan AA, Melis M, Walters J, Belinc D, Chen DT, et al. PET/CT fusion scan enhances CT staging in patients with pancreatic neoplasms. Ann Surg Oncol. 2008;15(9):2465–71.PubMedCrossRefGoogle Scholar
  142. 142.
    Im HJ, Oo S, Jung W, Jang JY, Kim SW, Cheon GJ, et al. Prognostic value of metabolic and volumetric parameters of preoperative FDG-PET/CT in patients with resectable pancreatic cancer. Medicine (Baltimore). 2016;95(19):e3686.CrossRefGoogle Scholar
  143. 143.
    Chen BB, Tien YW, Chang MC, Cheng MF, Chang YT, CH W, et al. PET/MRI in pancreatic and periampullary cancer: correlating diffusion-weighted imaging, MR spectroscopy and glucose metabolic activity with clinical stage and prognosis. Eur J Nucl Med Mol Imaging. 2016;43(10):1753–64.PubMedCrossRefGoogle Scholar
  144. 144.
    Choi Y, Oh DY, Park H, Kim TY, Lee KH, Han SW, et al. More accurate prediction of metastatic pancreatic cancer patients’ survival with prognostic model using both host immunity and tumor metabolic activity. PLoS One. 2016;11(1):e0145692.PubMedPubMedCentralCrossRefGoogle Scholar
  145. 145.
    Jung W, Jang JY, Kang MJ, Chang YR, Shin YC, Chang J, et al. The clinical usefulness of 18F-fluorodeoxyglucose positron emission tomography-computed tomography (PET-CT) in follow-up of curatively resected pancreatic cancer patients. HPB (Oxford). 2016;18(1):57–64.CrossRefGoogle Scholar
  146. 146.
    Hariharan D, Constantinides VA, Froeling FE, Tekkis PP, Kocher HM. The role of laparoscopy and laparoscopic ultrasound in the preoperative staging of pancreatico-biliary cancers – a meta-analysis. Eur J Surg Oncol. 2010;36(10):941–8.PubMedCrossRefGoogle Scholar
  147. 147.
    Society of American Gastrointestinal and Endoscopic Surgeons. Guidelines for diagnostic laparoscopy [July 8th, 2016].
  148. 148.
    Levy J, Tahiri M, Vanounou T, Maimon G, Bergman S. Diagnostic laparoscopy with ultrasound still has a role in the staging of pancreatic cancer: a systematic review of the literature. HPB Surg. 2016;2016:8092109.PubMedPubMedCentralCrossRefGoogle Scholar
  149. 149.
    Nakao A, Kanzaki A, Fujii T, Kodera Y, Yamada S, Sugimoto H, et al. Correlation between radiographic classification and pathological grade of portal vein wall invasion in pancreatic head cancer. Ann Surg. 2012;255(1):103–8.PubMedCrossRefGoogle Scholar
  150. 150.
    Winter JM, Cameron JL, Olino K, Herman JM, de Jong MC, Hruban RH, et al. Clinicopathologic analysis of ampullary neoplasms in 450 patients: implications for surgical strategy and long-term prognosis. J Gastrointest Surg. 2010;14(2):379–87.PubMedCrossRefGoogle Scholar
  151. 151.
    Varadhachary GR, Tamm EP, Abbruzzese JL, Xiong HQ, Crane CH, Wang H, et al. Borderline resectable pancreatic cancer: definitions, management, and role of preoperative therapy. Ann Surg Oncol. 2006;13(8):1035–46.PubMedCrossRefGoogle Scholar
  152. 152.
    Katz MH, Pisters PW, Evans DB, Sun CC, Lee JE, Fleming JB, et al. Borderline resectable pancreatic cancer: the importance of this emerging stage of disease. J Am Coll Surg. 2008;206(5):833–46. discussion 46-8.PubMedPubMedCentralCrossRefGoogle Scholar
  153. 153.
    Sourrouille I, Gaujoux S, Lacave G, Bert F, Dokmak S, Belghiti J, et al. Five days of postoperative antimicrobial therapy decreases infectious complications following pancreaticoduodenectomy in patients at risk for bile contamination. HPB (Oxford). 2013;15(6):473–80.CrossRefGoogle Scholar
  154. 154.
    D'Souza MA, Singh K, Hawaldar RV, Shukla PJ, Shrikhande SV. The vascular stapler in uncinate process division during pancreaticoduodenectomy: technical considerations and results. Dig Surg. 2010;27(3):175–81.PubMedCrossRefGoogle Scholar
  155. 155.
    Huttner FJ, Fitzmaurice C, Schwarzer G, Seiler CM, Antes G, Buchler MW, et al. Pylorus-preserving pancreaticoduodenectomy (pp Whipple) versus pancreaticoduodenectomy (classic Whipple) for surgical treatment of periampullary and pancreatic carcinoma. Cochrane Database Syst Rev. 2016;2:CD006053.PubMedGoogle Scholar
  156. 156.
    Barreto S. Classical or Pylorus-preserving pancreatoduodenectomy in pancreatic and periampullary cancer ‘the jury is still out!’. Indian J Med Paediatr Oncol. 2016;37(4):209–10.PubMedPubMedCentralCrossRefGoogle Scholar
  157. 157.
    Crippa S, Cirocchi R, Randolph J, Partelli S, Belfiori G, Piccioli A, et al. Pancreaticojejunostomy is comparable to pancreaticogastrostomy after pancreaticoduodenectomy: an updated meta-analysis of randomized controlled trials. Langenbeck’s Arch Surg. 2016;401(4):427–37.CrossRefGoogle Scholar
  158. 158.
    Sun X, Zhang Q, Zhang J, Lou Y, Fu Q, Zhang X, et al. Meta-analysis of invagination and duct-to-mucosa pancreaticojejunostomy after pancreaticoduodenectomy: an update. Int J Surg. 2016;36(Pt A):240–7.PubMedCrossRefGoogle Scholar
  159. 159.
    Shrikhande SV, Barreto G, Shukla PJ. Pancreatic fistula after pancreaticoduodenectomy: the impact of a standardized technique of pancreaticojejunostomy. Langenbeck’s Arch Surg. 2008;393(1):87–91.CrossRefGoogle Scholar
  160. 160.
    Imamura M, Kimura Y, Ito T, Kyuno T, Nobuoka T, Mizuguchi T, et al. Effects of antecolic versus retrocolic reconstruction for gastro/duodenojejunostomy on delayed gastric emptying after pancreatoduodenectomy: a systematic review and meta-analysis. J Surg Res. 2016;200(1):147–57.PubMedCrossRefGoogle Scholar
  161. 161.
    Tol J, Gouma D, Bassi C. Definition of a standard lymphadenectomy in surgery for pancreatic ductal adenocarcinoma: a consensus statement by the International Study Group on Pancreatic Surgery (ISGPS). Surgery. 2014;156:591–600.PubMedCrossRefGoogle Scholar
  162. 162.
    Dasari BV, Pasquali S, Vohra RS, Smith AM, Taylor MA, Sutcliffe RP, et al. Extended versus standard lymphadenectomy for pancreatic head cancer: meta-analysis of randomized controlled trials. J Gastrointest Surg. 2015;19(9):1725–32.PubMedCrossRefGoogle Scholar
  163. 163.
    Brennan MF, Moccia RD, Klimstra D. Management of adenocarcinoma of the body and tail of the pancreas. Ann Surg. 1996;223(5):506–11. discussion 11-2.PubMedPubMedCentralCrossRefGoogle Scholar
  164. 164.
    Shoup M, Brennan MF, McWhite K, Leung DH, Klimstra D, Conlon KC. The value of splenic preservation with distal pancreatectomy. Arch Surg. 2002;137(2):164–8.PubMedCrossRefGoogle Scholar
  165. 165.
    Christein JD, Kendrick ML, Iqbal CW, Nagorney DM, Farnell MB. Distal pancreatectomy for resectable adenocarcinoma of the body and tail of the pancreas. J Gastrointest Surg. 2005;9(7):922–7.PubMedCrossRefGoogle Scholar
  166. 166.
    Sasson AR, Hoffman JP, Ross EA, Kagan SA, Pingpank JF, Eisenberg BL. En bloc resection for locally advanced cancer of the pancreas: is it worthwhile? J Gastrointest Surg. 2002;6(2):147–57. discussion 57-8.PubMedCrossRefGoogle Scholar
  167. 167.
    Shoup M, Conlon KC, Klimstra D, Brennan MF. Is extended resection for adenocarcinoma of the body or tail of the pancreas justified? J Gastrointest Surg. 2003;7(8):946–52. discussion 52.PubMedCrossRefGoogle Scholar
  168. 168.
    Hartwig W, Hackert T, Hinz U, Hassenpflug M, Strobel O, Buchler MW, et al. Multivisceral resection for pancreatic malignancies: risk-analysis and long-term outcome. Ann Surg. 2009;250(1):81–7.PubMedCrossRefGoogle Scholar
  169. 169.
    Shrikhande SV, Barreto SG. Extended pancreatic resections and lymphadenectomy: an appraisal of the current evidence. World J Gastrointest Surg. 2010;2(2):39–46.PubMedPubMedCentralCrossRefGoogle Scholar
  170. 170.
    Diener MK, Seiler CM, Rossion I, Kleeff J, Glanemann M, Butturini G, et al. Efficacy of stapler versus hand-sewn closure after distal pancreatectomy (DISPACT): a randomised, controlled multicentre trial. Lancet. 2011;377(9776):1514–22.PubMedCrossRefGoogle Scholar
  171. 171.
    Probst P, Huttner FJ, Klaiber U, Knebel P, Ulrich A, Buchler MW, et al. Stapler versus scalpel resection followed by hand-sewn closure of the pancreatic remnant for distal pancreatectomy. Cochrane Database Syst Rev. 2015;11:CD008688.Google Scholar
  172. 172.
    Cecka F, Jon B, Subrt Z, Ferko A. Surgical technique in distal pancreatectomy: a systematic review of randomized trials. Biomed Res Int. 2014;2014:482906.PubMedPubMedCentralCrossRefGoogle Scholar
  173. 173.
    Maurer CA, Zgraggen K, Buchler MW. Pancreatic carcinoma. Optimizing therapy by adjuvant and neoadjuvant therapy? Zentralbl Chir. 1999;124(5):401–7.PubMedGoogle Scholar
  174. 174.
    Callery MP, Chang KJ, Fishman EK, Talamonti MS, William Traverso L, Linehan DC. Pretreatment assessment of resectable and borderline resectable pancreatic cancer: expert consensus statement. Ann Surg Oncol. 2009;16(7):1727–33.PubMedCrossRefGoogle Scholar
  175. 175.
    Tempero M, Arnoletti J, Behrman S, Ben-Josef E, Benson AB, Casper E. Pancreatic adenocarcinoma, version 2.2012: featured updates to the NCCN guidelines. J Natl Compr Cancer Netw. 2012;10:703–13.CrossRefGoogle Scholar
  176. 176.
    Katz MH, Marsh R, Herman JM, Shi Q, Collison E, Venook AP, et al. Borderline resectable pancreatic cancer: need for standardization and methods for optimal clinical trial design. Ann Surg Oncol. 2013;20(8):2787–95.PubMedPubMedCentralCrossRefGoogle Scholar
  177. 177.
    Al-Hawary MM, Francis IR, Chari ST, Fishman EK, Hough DM, Lu DS, et al. Pancreatic ductal adenocarcinoma radiology reporting template: consensus statement of the society of abdominal radiology and the american pancreatic association. Gastroenterology. 2014;146(1):291–304 e1.PubMedCrossRefGoogle Scholar
  178. 178.
    Varadhachary G, Fleming J, Crane C, Fogelman D, Shroff R, Lee J, et al. Phase II study of preoperation mFOLFIRINOX and chemoradiation for high-risk resectable and borderline resectable pancreatic adenocarcinoma. J Clin Oncol. 2015;33(suppl 3):362.CrossRefGoogle Scholar
  179. 179.
    Katz MH, Fleming JB, Bhosale P, Varadhachary G, Lee JE, Wolff R, et al. Response of borderline resectable pancreatic cancer to neoadjuvant therapy is not reflected by radiographic indicators. Cancer. 2012;118(23):5749–56.PubMedCrossRefGoogle Scholar
  180. 180.
    Barreto SG, Windsor JA. Justifying vein resection with pancreatoduodenectomy – author’s reply. Lancet Oncol. 2016;17(5):e178.PubMedCrossRefGoogle Scholar
  181. 181.
    Fortner J. Regional resection of cancer of the pancreas: a new surgical approach. Surgery. 1973;73:307.PubMedGoogle Scholar
  182. 182.
    Kaneoka Y, Yamaguchi A, Isogai M. Portal or superior mesenteric vein resection for pancreatic head adenocarcinoma: prognostic value of the length of venous resection. Surgery. 2009;145(4):417–25.PubMedCrossRefGoogle Scholar
  183. 183.
    Latona JA, Lamb KM, Pucci MJ, Maley WR, Yeo CJ. Modified Appleby procedure with arterial reconstruction for locally advanced pancreatic adenocarcinoma: a literature review and report of three unusual cases. J Gastrointest Surg. 2016;20(2):300–6.PubMedCrossRefGoogle Scholar
  184. 184.
    Kato H, Usui M, Isaji S, Nagakawa T, Wada K, Unno M, et al. Clinical features and treatment outcome of borderline resectable pancreatic head/body cancer: a multi-institutional survey by the Japanese Society of Pancreatic Surgery. J Hepatobiliary Pancreat Sci. 2013;20(6):601–10.PubMedCrossRefGoogle Scholar
  185. 185.
    Mollberg N, Rahbari NN, Koch M, Hartwig W, Hoeger Y, Buchler MW, et al. Arterial resection during pancreatectomy for pancreatic cancer: a systematic review and meta-analysis. Ann Surg. 2011;254(6):882–93.PubMedCrossRefGoogle Scholar
  186. 186.
    Ravikumar R, Holroyd D, Fusai G. Is there a role for arterial reconstruction in surgery for pancreatic cancer? World J Gastrointest Surg. 2013;5(3):27–9.PubMedPubMedCentralCrossRefGoogle Scholar
  187. 187.
    Giovinazzo F, Turri G, Katz MH, Heaton N, Ahmed I. Meta-analysis of benefits of portal-superior mesenteric vein resection in pancreatic resection for ductal adenocarcinoma. Br J Surg. 2016;103(3):179–91.PubMedCrossRefGoogle Scholar
  188. 188.
    Bockhorn M, Uzunoglu F, Adham M, Imrie C. Borderline resectable pancreatic cancer: a consensus statement by the International Study Group of Pancreatic Surgery (ISGPS). Surgery. 2014;155(6):977–88.PubMedCrossRefGoogle Scholar
  189. 189.
    Fukuda S, Oussoultzoglou E, Bachellier P, Rosso E, Nakano H, Audet M, et al. Significance of the depth of portal vein wall invasion after curative resection for pancreatic adenocarcinoma. Arch Surg. 2007;142(2):172–9. discussion 80.PubMedCrossRefGoogle Scholar
  190. 190.
    Sanjay P, Takaori K, Govil S, Shrikhande S, Windsor J. ‘Artery-first’ approaches to pancreatoduodenectomy. Br J Surg. 2012;99(8):1027–35.PubMedCrossRefGoogle Scholar
  191. 191.
    Shrikhande SV, Kleeff J, Reiser C, Weitz J, Hinz U, Esposito I, et al. Pancreatic resection for M1 pancreatic ductal adenocarcinoma. Ann Surg Oncol. 2007;14(1):118–27.PubMedCrossRefGoogle Scholar
  192. 192.
    Michalski CW, Erkan M, Huser N, Muller MW, Hartel M, Friess H, et al. Resection of primary pancreatic cancer and liver metastasis: a systematic review. Dig Surg. 2008;25(6):473–80.PubMedCrossRefGoogle Scholar
  193. 193.
    Gleisner AL, Assumpcao L, Cameron JL, Wolfgang CL, Choti MA, Herman JM, et al. Is resection of periampullary or pancreatic adenocarcinoma with synchronous hepatic metastasis justified? Cancer. 2007;110(11):2484–92.PubMedCrossRefGoogle Scholar
  194. 194.
    Paiella S, Sandini M, Gianotti L, Butturini G, Salvia R, Bassi C. The prognostic impact of para-aortic lymph node metastasis in pancreatic cancer: a systematic review and meta-analysis. Eur J Surg Oncol. 2016;42(5):616–24.PubMedCrossRefGoogle Scholar
  195. 195.
    de Jong MC, Tsai S, Cameron JL, Wolfgang CL, Hirose K, van Vledder MG, et al. Safety and efficacy of curative intent surgery for peri-ampullary liver metastasis. J Surg Oncol. 2010;102(3):256–63.PubMedCrossRefGoogle Scholar
  196. 196.
    Sulpice L, Farges O, Goutte N, Bendersky N, Dokmak S, Sauvanet A, et al. Laparoscopic distal pancreatectomy for pancreatic ductal adenocarcinoma: time for a randomized controlled trial? Results of an all-inclusive National Observational Study. Ann Surg. 2015;262(5):868–73. discussion 73-4.PubMedCrossRefGoogle Scholar
  197. 197.
    Baker MS, Bentrem DJ, Ujiki MB, Stocker S, Talamonti MS. Adding days spent in readmission to the initial postoperative length of stay limits the perceived benefit of laparoscopic distal pancreatectomy when compared with open distal pancreatectomy. Am J Surg. 2011;201(3):295–9. discussion 9-300.PubMedCrossRefGoogle Scholar
  198. 198.
    Liao CH, Wu YT, Liu YY, Wang SY, Kang SC, Yeh CN, et al. Systemic review of the feasibility and advantage of minimally invasive pancreaticoduodenectomy. World J Surg. 2016;40(5):1218–25.PubMedCrossRefGoogle Scholar
  199. 199.
    Kendrick ML. Laparoscopic and robotic resection for pancreatic cancer. Cancer J. 2012;18(6):571–6.PubMedCrossRefGoogle Scholar
  200. 200.
    Shrikhande SV, Barreto SG, Shukla PJ. Laparoscopy in pancreatic tumors. J Minim Access Surg. 2007;3(2):47–51.PubMedPubMedCentralCrossRefGoogle Scholar
  201. 201.
    Bassi C, Dervenis C, Butturini G, Fingerhut A, Yeo C, Izbicki J, et al. Postoperative pancreatic fistula: an international study group (ISGPF) definition. Surgery. 2005;138(1):8–13.PubMedCrossRefGoogle Scholar
  202. 202.
    Wente MN, Bassi C, Dervenis C, Fingerhut A, Gouma DJ, Izbicki JR, et al. Delayed gastric emptying (DGE) after pancreatic surgery: a suggested definition by the International Study Group of Pancreatic Surgery (ISGPS). Surgery. 2007;142(5):761–8.PubMedCrossRefGoogle Scholar
  203. 203.
    Wente MN, Veit JA, Bassi C, Dervenis C, Fingerhut A, Gouma DJ, et al. Postpancreatectomy hemorrhage (PPH): an International Study Group of Pancreatic Surgery (ISGPS) definition. Surgery. 2007;142(1):20–5.PubMedCrossRefGoogle Scholar
  204. 204.
    Barreto S. Quality improvement – the key to reducing costs in pancreatoduodenectomy. JOP. 2016;17:154–9.Google Scholar
  205. 205.
    Shirai Y, Shiba H, Horiuchi T, Saito N, Furukawa K, Sakamoto T, et al. Assessment of outcome after pancreaticoduodenectomy by Junior Surgeons. Anticancer Res. 2016;36(7):3505–10.PubMedGoogle Scholar
  206. 206.
    Birkmeyer JD, Siewers AE, Finlayson EV, Stukel TA, Lucas FL, Batista I, et al. Hospital volume and surgical mortality in the United States. N Engl J Med. 2002;346(15):1128–37.PubMedCrossRefGoogle Scholar
  207. 207.
    Shukla PJ, Barreto SG, Bedi M, Bheerappa N, Chaudhary A, Gandhi M, et al. Peri-operative outcomes for pancreatoduodenectomy in India: a multi-centric study. HPB (Oxford). 2009;11(8):638–44.CrossRefGoogle Scholar
  208. 208.
    Coolsen MM, van Dam RM, van der Wilt AA, Slim K, Lassen K, Dejong CH. Systematic review and meta-analysis of enhanced recovery after pancreatic surgery with particular emphasis on pancreaticoduodenectomies. World J Surg. 2013;37(8):1909–18.PubMedCrossRefGoogle Scholar
  209. 209.
    Chaudhary A, Barreto S, Talole S, Singh A, Perwaiz A, Singh T. Early discharge after pancreatoduodenectomy – what helps and what prevents? Pancreas. 2015;44:273–8.PubMedCrossRefGoogle Scholar
  210. 210.
    Shrikhande SV, Barreto SG, Shetty G, Suradkar K, Bodhankar YD, Shah SB, et al. Post-operative abdominal drainage following major upper gastrointestinal surgery: single drain versus two drains. J Cancer Res Ther. 2013;9(2):267–71.PubMedCrossRefGoogle Scholar
  211. 211.
    McMillan MT, Malleo G, Bassi C, Allegrini V, Casetti L, Drebin JA, et al. Multicenter, prospective trial of selective drain management for pancreatoduodenectomy using risk stratification. Ann Surg. 2016;265(6):1209–18.CrossRefGoogle Scholar
  212. 212.
    Martin R. Use of irreversible electroporation in unresectable pancreatic cancer. Hepatobiliary Surg Nutr. 2015;4(3):211–5.PubMedPubMedCentralGoogle Scholar
  213. 213.
    Martin R, Kwon D, Chalikonda S, Sellers M, Kotz E, Scoggins C, et al. Treatment of 200 locally advanced (Stage III) pancreatic adenocarcinoma patients with irreversible electroporation: safety and efficacy. Ann Surg. 2015;262(3):486–94.PubMedCrossRefGoogle Scholar
  214. 214.
    Kwon D, McFarland K, Velanovich V, Martin R. Borderline and locally advanced pancreatic adenocarcinoma margin accentuation with intraoperative irreversible electroporation. Surgery. 2014;156(4):910–20.PubMedCrossRefGoogle Scholar
  215. 215.
    O'Neill B, Fallon M. ABC of palliative care. Principles of palliative care and pain control. BMJ. 1997;315(7111):801–4.PubMedPubMedCentralCrossRefGoogle Scholar
  216. 216.
    Miner TJ, Jaques DP, Shriver CD. A prospective evaluation of patients undergoing surgery for the palliation of an advanced malignancy. Ann Surg Oncol. 2002;9(7):696–703.PubMedCrossRefGoogle Scholar
  217. 217.
    Buettner S, Wilson A, Margonis GA, Gani F, Ethun CG, Poultsides GA, et al. Assessing trends in palliative surgery for extrahepatic biliary malignancies: a 15-year multicenter study. J Gastrointest Surg. 2016;20(8):1444–52.PubMedPubMedCentralCrossRefGoogle Scholar
  218. 218.
    Syin D, Woreta T, Chang DC, Cameron JL, Pronovost PJ, Makary MA. Publication bias in surgery: implications for informed consent. J Surg Res. 2007;143(1):88–93.PubMedCrossRefGoogle Scholar
  219. 219.
    Ausania F, Vallance AE, Manas DM, Prentis JM, Snowden CP, White SA, et al. Double bypass for inoperable pancreatic malignancy at laparotomy: postoperative complications and long-term outcome. Ann R Coll Surg Engl. 2012;94(8):563–8.PubMedPubMedCentralCrossRefGoogle Scholar
  220. 220.
    Lima SA, Bustamante F, Moura EH, Bernardo W, Artifon E, Chaves D, et al. Endoscopic palliative treatment versus surgical bypass in malignant low bile duct obstruction: a systematic review and meta-analysis. Int J Hepatobiliary Pancreat Dis. 2015;5:35–46.CrossRefGoogle Scholar
  221. 221.
    Lyons JM, Karkar A, Correa-Gallego CC, D’Angelica MI, DeMatteo RP, Fong Y, et al. Operative procedures for unresectable pancreatic cancer: does operative bypass decrease requirements for postoperative procedures and in-hospital days? HPB (Oxford). 2012;14(7):469–75.CrossRefGoogle Scholar
  222. 222.
    Glant J, Waters J, House M, Zyromski N, Nakeeb A, Pitt H, et al. Does the interval from imaging to operation affect the rate of unanticipated metastasis encountered during operation for pancreatic adenocarcinoma? Surgery. 2011;150(4):607–16.PubMedCrossRefGoogle Scholar
  223. 223.
    Gurusamy K, Kumar S, Davidson B. Prophylactic gastrojejunostomy for unresectable periampullary carcinoma. Cochrane Database Syst Rev. 2013;2:CD008533.Google Scholar
  224. 224.
    Huser N, Michalski C, Schuster T, Friess H, Kleeff J. Systematic review and meta-analysis of prophylactic gastroenterstomy for unresectable advanced pancreatic cancer. Br J Surg. 2009;96(7):711–9.PubMedCrossRefGoogle Scholar
  225. 225.
    Barreto SG, Saccone GT. Pancreatic nociception – revisiting the physiology and pathophysiology. Pancreatology. 2012;12(2):104–12.PubMedCrossRefGoogle Scholar
  226. 226.
    Arcidiacono PG, Calori G, Carrara S, McNicol ED, Testoni PA. Celiac plexus block for pancreatic cancer pain in adults. Cochrane Database Syst Rev. 2011;3:CD007519.Google Scholar
  227. 227.
    Ueno H, Kosuge T, Matsuyama Y, Yamamoto J, Nakao A, Egawa S, et al. A randomised phase III trial comparing gemcitabine with surgery-only in patients with resected pancreatic cancer: Japanese Study Group of Adjuvant Therapy for Pancreatic Cancer. Br J Cancer. 2009;101(6):908–15.PubMedPubMedCentralCrossRefGoogle Scholar
  228. 228.
    Regine WF, Winter KA, Abrams RA, Safran H, Hoffman JP, Konski A, et al. Fluorouracil vs gemcitabine chemotherapy before and after fluorouracil-based chemoradiation following resection of pancreatic adenocarcinoma: a randomized controlled trial. JAMA. 2008;299(9):1019–26.PubMedCrossRefGoogle Scholar
  229. 229.
    Oettle H, Post S, Neuhaus P, Gellert K, Langrehr J, Ridwelski K, et al. Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer: a randomized controlled trial. JAMA. 2007;297(3):267–77.PubMedCrossRefGoogle Scholar
  230. 230.
    Neoptolemos JP, Stocken DD, Friess H, Bassi C, Dunn JA, Hickey H, et al. A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer. N Engl J Med. 2004;350(12):1200–10.PubMedCrossRefGoogle Scholar
  231. 231.
    Neoptolemos JP, Stocken DD, Bassi C, Ghaneh P, Cunningham D, Goldstein D, et al. Adjuvant chemotherapy with fluorouracil plus folinic acid vs gemcitabine following pancreatic cancer resection: a randomized controlled trial. JAMA. 2010;304(10):1073–81.PubMedCrossRefGoogle Scholar
  232. 232.
    Klinkenbijl JH, Jeekel J, Sahmoud T, van Pel R, Couvreur ML, Veenhof CH, et al. Adjuvant radiotherapy and 5-fluorouracil after curative resection of cancer of the pancreas and periampullary region: phase III trial of the EORTC gastrointestinal tract cancer cooperative group. Ann Surg. 1999;230(6):776–82. discussion 82-4.PubMedPubMedCentralCrossRefGoogle Scholar
  233. 233.
    Kalser MH, Ellenberg SS. Pancreatic cancer. Adjuvant combined radiation and chemotherapy following curative resection. Arch Surg. 1985;120(8):899–903.PubMedCrossRefGoogle Scholar
  234. 234.
    Oettle H, Neuhaus P, Hochhaus A, Hartmann JT, Gellert K, Ridwelski K, et al. Adjuvant chemotherapy with gemcitabine and long-term outcomes among patients with resected pancreatic cancer: the CONKO-001 randomized trial. JAMA. 2013;310(14):1473–81.PubMedCrossRefGoogle Scholar
  235. 235.
    Uesaka K, Boku N, Fukutomi A, Okamura Y, Konishi M, Matsumoto I, et al. Adjuvant chemotherapy of S-1 versus gemcitabine for resected pancreatic cancer: a phase 3, open-label, randomised, non-inferiority trial (JASPAC 01). Lancet. 2016;388(10041):248–57.PubMedCrossRefGoogle Scholar
  236. 236.
    Shrikhande S, Barreto S. Surgical management of pancreatic cancer. In: Shrikhande S, Sirohi B, editors. Modern gastrointestinal oncology. New Delhi: Elsevier; 2015. p. 201–20.Google Scholar
  237. 237.
    Antoniou G, Kountourakis P, Papadimitriou K, Vassiliou V, Papamichael D. Adjuvant therapy for resectable pancreatic adenocarcinoma: review of the current treatment approaches and future directions. Cancer Treat Rev. 2013;40(1):78–85.PubMedCrossRefGoogle Scholar
  238. 238.
    Petrelli F, Coinu A, Borgonovo K, Cabiddu M, Ghilardi M, Lonati V, et al. FOLFIRINOX-based neoadjuvant therapy in borderline resectable or unresectable pancreatic cancer: a meta-analytical review of published studies. Pancreas. 2015;44(4):515–21.PubMedCrossRefGoogle Scholar
  239. 239.
    Haeno H, Gonen M, Davis MB, Herman JM, Iacobuzio-Donahue CA, Michor F. Computational modeling of pancreatic cancer reveals kinetics of metastasis suggesting optimum treatment strategies. Cell. 2012;148(1–2):362–75.PubMedPubMedCentralCrossRefGoogle Scholar
  240. 240.
    Rhim AD, Mirek ET, Aiello NM, Maitra A, Bailey JM, McAllister F, et al. EMT and dissemination precede pancreatic tumor formation. Cell. 2012;148(1–2):349–61.PubMedPubMedCentralCrossRefGoogle Scholar
  241. 241.
    Crippa S, Reni M, Balzano G, Doglioni C, Falconi M. Justifying vein resection with pancreatoduodenectomy. Lancet Oncol. 2016;17(5):e177.PubMedCrossRefGoogle Scholar
  242. 242.
    Hackert T, Sachsenmaier M, Hinz U, Schneider L, Michalski CW, Springfeld C, et al. Locally advanced pancreatic cancer: neoadjuvant therapy with folfirinox results in resectability in 60% of the patients. Ann Surg. 2016;264(3):457–63.PubMedCrossRefGoogle Scholar
  243. 243.
    Festa V, Andriulli A, Valvano MR, Uomo G, Perri F, Andriulli N, et al. Neoadjuvant chemo-radiotherapy for patients with borderline resectable pancreatic cancer: a meta-analytical evaluation of prospective studies. JOP. 2013;14(6):618–25.PubMedGoogle Scholar
  244. 244.
    Cloyd JM, Crane CH, Koay EJ, Das P, Krishnan S, Prakash L, et al. Impact of hypofractionated and standard fractionated chemoradiation before pancreatoduodenectomy for pancreatic ductal adenocarcinoma. Cancer. 2016;122(17):2671–9.PubMedPubMedCentralCrossRefGoogle Scholar
  245. 245.
    Tang K, Lu W, Qin W, Wu Y. Neoadjuvant therapy for patients with borderline resectable pancreatic cancer: a systematic review and meta-analysis of response and resection percentages. Pancreatology. 2016;16(1):28–37.PubMedCrossRefGoogle Scholar
  246. 246.
    Versteijne E, van Eijck CH, Punt CJ, Suker M, Zwinderman AH, Dohmen MA, et al. Preoperative radiochemotherapy versus immediate surgery for resectable and borderline resectable pancreatic cancer (PREOPANC trial): study protocol for a multicentre randomized controlled trial. Trials. 2016;17(1):127.PubMedPubMedCentralCrossRefGoogle Scholar
  247. 247.
    Strobel O, Berens V, Hinz U, Hartwig W, Hackert T, Bergmann F, et al. Resection after neoadjuvant therapy for locally advanced, “unresectable” pancreatic cancer. Surgery. 2012;152(3 Suppl 1):S33–42.PubMedCrossRefGoogle Scholar
  248. 248.
    Chuong MD, Frakes JM, Figura N, Hoffe SE, Shridhar R, Mellon EA, et al. Histopathologic tumor response after induction chemotherapy and stereotactic body radiation therapy for borderline resectable pancreatic cancer. J Gastrointest Oncol. 2016;7(2):221–7.PubMedPubMedCentralGoogle Scholar
  249. 249.
    Verma V, Li J, Lin C. Neoadjuvant therapy for pancreatic cancer: systematic review of postoperative morbidity, mortality, and complications. Am J Clin Oncol. 2016;39(3):302–13.PubMedCrossRefGoogle Scholar
  250. 250.
    Burris HA, Moore MJ, Andersen J, Green MR, Rothenberg ML, Modiano MR, et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol. 1997;15(6):2403–13.PubMedCrossRefGoogle Scholar
  251. 251.
    Moore MJ, Goldstein D, Hamm J, Figer A, Hecht JR, Gallinger S, et al. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol. 2007;25(15):1960–6.PubMedCrossRefGoogle Scholar
  252. 252.
    Gourgou-Bourgade S, Bascoul-Mollevi C, Desseigne F, Ychou M, Bouche O, Guimbaud R, et al. Impact of FOLFIRINOX compared with gemcitabine on quality of life in patients with metastatic pancreatic cancer: results from the PRODIGE 4/ACCORD 11 randomized trial. J Clin Oncol. 2013;31(1):23–9.PubMedCrossRefGoogle Scholar
  253. 253.
    Attard CL, Brown S, Alloul K, Moore MJ. Cost-effectiveness of folfirinox for first-line treatment of metastatic pancreatic cancer. Curr Oncol. 2014;21(1):e41–51.PubMedPubMedCentralCrossRefGoogle Scholar

Copyright information

© Springer Nature Singapore Pte Ltd. 2018

Authors and Affiliations

  • Savio George Barreto
    • 1
    • 2
  1. 1.Department of Gastrointestinal Surgery, Gastrointestinal Oncology, and Bariatric SurgeryMedanta Institute of Digestive and Hepatobiliary SciencesGurgaonIndia
  2. 2.College of Medicine and Public HealthFlinders UniversityBedford ParkAustralia

Personalised recommendations